Evan Latourrette, DPM
Primary Podiatric Medicine · Ronkonkoma, NYNPI 1396266516
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,400 of the $3,822 with a category attached, or 62.8%. Prodigy Surgical Distribution, Inc. accounts for 62.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $2,601 and has fallen 83.3% since, to $435 in 2025.
Across 37 payments — averaging $103.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Prodigy Surgical Distribution, Inc.$2K
- Stryker$264
- Advanced Oxygen Therapy Inc.$174
- AstraZeneca$131
- Boston Scientific$125
- Amgen$125
- plus $603 from 16 others
What the payments were for
- Travel & lodging$170%
- Food & beverage$1,40437%
- Education$2,40063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Prodigy Surgical Distribution, Inc. | 2 | $2,400 |
| Stryker | 4 | $264 |
| Advanced Oxygen Therapy Inc. | 4 | $174 |
| AstraZeneca | 2 | $131 |
| Boston Scientific | 1 | $125 |
| Amgen | 1 | $125 |
| Novo Nordisk | 1 | $114 |
| Misonix Inc | 2 | $81 |
| Paratek Pharmaceuticals, Inc. | 4 | $72 |
| Corcept Therapeutics | 2 | $69 |
| Exact Sciences | 2 | $51 |
| DJO, LLC | 1 | $38 |
| Bioventus LLC | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Fidia Pharma USA Inc. | 1 | $23 |
| Merck | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Musculoskeletal Transplant Foundation Inc. | 2 | $17 |
| Baxter Healthcare | 1 | $15 |
| Smith+Nephew | 1 | $13 |
| Biotissue Holdings Inc. | 1 | $12 |
| Nabriva Therapeutics, PLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,822 in reported general payments places this provider in the 85th percentile of 85 primary podiatric medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 100 | $2,878 |
| Econazole Nitrate | 14 | $765 |
| Ammonium Lactate | 13 | $250 |
| Gabapentin | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Other primary podiatric medicine in Ronkonkoma
- Anthony IorioNorth Salem$177K
- Brian StraussYonkers$20K
- Martin WendelkenBronx$14K
- Nicholas MegdanisBayside$12K
- Carlos SilvaWoodhaven$5K
- Edgard NauNew York$5K
- Roy DefrancisCheektowaga$4K
- Allen FungStaten Island$4K
- Lina DobronevskyManhasset$4K
- Michael MerensteinBronx$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.